Rhythm Pharmaceuticals initiated at Morgan Stanley

Rhythm Pharmaceuticals resumed with an Overweight at Morgan Stanley. Morgan Stanley analyst David Lebowitz resumed coverage of Rhythm Pharmaceuticals with an Overweight rating and $38 price target, stating that early data suggest setmelanotide could be approvable as a therapy for ultra-rare forms of obesity. Collectively, MC4 pathway obesity disorders represent $1B in potential sales, the analyst estimates.
https://thefly.com/landingPageNews.php?id=2787263